





		Funding contribution (million)			million)
Initiative/Activity	Institution	MRFF projects	Non- MRFF projects	Total committed to projects/grant opportunities to date <sup>6</sup>	Total allocated to Mission <sup>7</sup>
Australian Government - MRFF					
Zero Childhood Cancer Initiative	University of New South Wales	\$5.00		\$62.01 <sup>5</sup>	\$80.26
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) <sup>1</sup>	Monash University	\$3.01			
Cooperative Trials Group for Neuro-Oncology (COGNO)	University of Sydney	\$2.50			
COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs <sup>2</sup>	Monash University	\$0.13			
SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, molecularly-targeted CHK1/2i Therapy, in combination with cyclophosphamide or gemcitabine for children and adolescents with refractory or recurrent medulloblastoma brain tumours <sup>3</sup>	Monash University	\$0.23			
MAGMA: Multi-Arm GlioblastoMa Australasia Trial <sup>4</sup>	University of Sydney	\$1.27			
PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH- mutant high-grade Glioma	University of Sydney	\$1.39			
FET-PET in Glioma (FIG Study)	La Trobe University	\$1.25			
LUMOS: Low & intermediate grade glioma umbrella study of molecular guided therapies	University of Sydney	\$0.50			
Role of the NKp44-PDGF-DD axis in glioblastoma	University of Melbourne	\$0.57			
PARC: A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) relapsed/refractory cancers of children and young adults	Monash University	\$0.48			
Targeting invadapodia to treat glioblastoma	University of Melbourne	\$0.38			
BRAIN: Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs	University of Sydney	\$4.97			
A new nurse-led intervention to re-engage childhood brain cancer survivors	University of New South Wales	\$1.94			
Responding to need: technology-enhanced brain cancer survivorship	University of Melbourne	\$2.62			

MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients	Monash University	\$0.88			
CONNECT 1903: A pilot and surgical study of larotrectinib for disease control in children with newly-diagnosed high-grade glioma with NTRK fusion	Monash University	\$0.32			
LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents	University of New South Wales	\$1.13			
LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	University of Sydney	\$1.98			
GLIMMER: Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform	The Walter and Eliza Hall Institute of Medical Research	\$4.55			
A new targeted combination therapy with matched biomarker to treat intractable glioblastoma	University of New South Wales	\$0.58			
"Off-the-shelf" CAR-T cell immunotherapy for brain cancer	The Council of the Queensland Institute of Medical Research	\$0.33			
Supporting Australian Brain Cancer Research with an integrated network of platforms	University of Sydney	\$5.99			
ACT Health and Canberra Health Services					
Provision of a Brain Cancer Specialist Nurse	Canberra Health Service		\$0.36	\$1.82	\$3.95
Provision of stereotactic treatment	Canberra Health Service		\$0.30		
Brain tumour multi-disciplinary team meeting	Canberra Health Service		\$0.29		
Brain tumour multi-disciplinary meeting	Canberra Health Service		\$0.14		
Canberra Health services research and clinical trials	Canberra Health Service		\$0.14		
Research grant: Research and innovation fund	ACT Health Directorate		\$0.29		
Research grant: Research and innovation fund	ACT Health Directorate		\$0.30		
Carrie's Beanies 4 Brain Cancer		-			
MAGMA <sup>4</sup>	University of Sydney	\$0.65		\$5.40	\$5.40

SJ-ELIOT <sup>3</sup>	Monash University	\$0.23			
COZMOS <sup>2</sup>	Monash University	\$0.12			
Australian and New Zealand Children's Haematology/ Oncology Group (ANZCHOG) <sup>1</sup>	Monash University	\$0.40			
The Brain Cancer Centre	WEHI		\$4.00		
Children's Hospital Foundation Queensland					
Exploiting CDK 4/6 inhibition to treat medulloblastoma	University of Queensland		\$0.20	\$6.09	\$10.00
New strategies for targeting immune evasion in children's brain tumours	University of Queensland		\$0.10		
Integrating innovative models of the brain microenvironment to identify new treatment strategies for medulloblastoma	University of Queensland		\$0.05		
Unallocated - research tbc	The University of Queensland; Queensland University of Technology; QIMR Berghofer & CHQ		\$1.11		
Assessment of the Novel OLIG2 Inhibitor CT179 as an EffectiveTherapy for Paediatric Medulloblastoma	QIMR Berghofer		\$0.50		
EphA3 a Valid Tumour Specific Therapeutic Target for Paediatric Brain Cancer	QIMR Berghofer		\$0.53		
Effects of therapeutic exercise in paediatric survivors of childhood posterior fossa brain tumors	Queensland University of Technology		\$0.32		
Addressing survivorship and palliative care needs in children and adolescents with brain cancer	Queensland University of Technology		\$0.32		
Developing novel therapeutic approaches for treatment of vincristine-induced neuropathy	The University of Queensland		\$1.01		
Risk factors for speech and language impairments and long term outcomes in survivors of childhood primary posterior fossa tumours	Queensland University of Technology		\$0.33		

Embryonal Tumours with Multilayered Rosettes - basic biology and tools for translation	The University of Queensland		\$0.20		
Shared Program Resources for Centre for Child and Adolescent Brain Cancer Research	The University of Queensland; Queensland University of Technology; QIMR Berghofer & CHQ		\$1.00		
Small-Animal Micro-Irradiation Facility	University of Queensland, Queensland University of Technology, Mater Medical Research Institute and Queensland Health		\$0.30		
A new and effective combination therapy for children with brain cancer	University of Queensland		\$0.11		
Functional genomics identifies clinically actionable novel therapeutic targets for all non-WNT medulloblastoma (travel grant)	University of Queensland		\$0.01		
Cure Brain Cancer Foundation					\$20.00
Financial Markets Foundation for Children					
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) <sup>1</sup>	Monash University	\$5.00		\$5.00	\$5.00
The Kids' Cancer Project	•				
Development of personalised medicine approaches to treat medulloblastoma, Professor Bryan Day	QIMR		\$0.47	\$6.07	\$5.30
New therapies for incurable paediatric brain tumours, Professor Brandon Wainwright	Institute of Molecular Bioscience		\$0.48		
Novel therapies for diffuse intrinsic pontine glioma (DIPG), A/Professor David Ziegler	Children's Cancer Institute & Sydney Children's Hospital		\$0.27		

Using targeted chemotherapies to reduce intensity of radiotherapy in medulloblastoma, Dr Nick Gottardo	Telethon Kids Institute	\$0.26	
Epigenetic targeted therapy in Diffuse Intrinsic Pontine Glioma (DIPG) A/Professor David Ziegler	Children's Cancer Institute	\$0.25	
Targeting novel therapeutic opportunities for diffuse intrinsic pontine glioma (DIPG), A/Professor David Ziegler	Children's Cancer Institute	\$0.28	
Application of gene-silencing nanodrugs to inhibit medulloblastoma growth, A/Professor Joshua McCarroll	Children's Cancer Institute	\$0.30	
Using modern targeted chemotherapies to reduce the intensity of radiotherapy in medulloblastoma and decrease treatment-related side effects, Dr Nick Gottardo	Telethon Kids Institute	\$0.13	
3D printers and mini-brains. New approaches for brain cancer research. Geraldine O'Neill	The Children's Hospital at Westmead	\$0.12	
Pre-clinical anti CD-47 therapy for High Grade Glioma, Dr Nick Gottardo	Telethon Kids Institute	\$0.10	
Connect 1903 Clinical trial - Dr Nick Gottardo	ANZCHOG	\$0.05	
Dr Elizabeth Hovey - Personalised targeted therapy for adolescent and young adult medulloblastoma patients	Nelune Comprehensive Cancer Centre	\$0.17	
Dr Nick Gottardo - Using smarter new drugs to reduce long term debilitating side effects for aggressive childhood brain cancer	Telethon Kids Institute	\$0.11	
Matt Dun - Pharmaco-phospho-proteo-genomics of paediatric high-grade glioma	University of Newcastle	\$0.30	
Danielle Upton - Targeting the thioredoxin system as a novel strategy for Diffuse Intrinsic Pontine Glioma	Children's Cancer Institute	\$0.33	
Nick Gottardo - Enhancing radiation therapy using brain specific immunotherapy to improve survival outcomes for children with aggressive brain cancer.	Telethon Kids Institute	\$0.11	
Targeting the DC-T cell axis to treat glioblastoma, Dr Tessa Garret	Royal Adelaide Hospital	\$0.30	

Discovering new ways to treat deadly childhood brain cancers by understanding the immune system, A/Professor Raelene Endesby	Telethon Kids Institute		\$0.12		
A new and effective combination therapy for children with brain cancer, Professor Brandon Wainwright	Institute of Molecular Bioscience		\$0.24		
Polyamine pathway inhibition as a targeted therapy for MYC-amplified medulloblastoma in paediatric patients, Aaminah Khan	Children's Cancer Institute		\$0.46		
Developing novel treatments for high-risk childhood brain cancer, Dr Marion Mateos	Kids Cancer Centre Sydney Children's Hospital		\$0.28		
Precision neurosurgical image-guidance: improving the outcomes of childhood brain tumour surgery using artificial intelligence-based automated MRI tractography, Joseph Yuan-Mou Yang	Murdoch Children's Research Institute		\$0.28		
Dissecting drug resistance and guiding targeted therapy in paediatric gliomas -PhD Scholarsip top-up, Philipp Graber	Children's Cancer Institute		\$0.04		
Identify a novel low toxicity therapy for high-grade glioma patients to improve the post-treatment quality of lifeKenny Chi Kin Ip	Children's Cancer Institute		\$0.62		
Mark Hughes Foundation					
MAGMA⁴	University of Sydney	\$0.50		\$1.17	\$3.00
The IWOT study: treating lower grade glioma?	University of Sydney		\$0.10		
Glioblastoma: Determining how the molecular microenvironment of the human brain influences cancer progression and treatment efficacy	Flinders University		\$0.57		
Minderoo Foundation					
Zero Childhood Cancer 1.0	Children's Cancer Institute		\$5.00	\$10.79	\$10.00
Zero Childhood Cancer 2.0 (30% of \$12.2M grant relevant to brain tumour patients)	Children's Cancer Institute		\$3.66		
Molecular Screening and Therapeutics (MoST) substudies	OMICO/AGCMC Limited		\$1.40		
Unrestricted research grant (Snow Ball Donation)	Tour de Cure		\$0.03		
Unrestricted research grant (matched fundraising)	Cure Brain Cancer Foundation		\$0.20		

Unrestricted research grant (matched fundraising)	Cure Brain Cancer Foundation	\$0.30		
Unrestricted research grant (Charlie Teo WA Ball Donation)	Charlie Teo Foundation	\$0.20		
NeuroSurgical Research Foundation		•		
Immunotherapy Glioblastoma (CAR)-T Dr Lisa Ebert	University of South Australia	\$0.06	\$2.88	\$3.00
A new approach to deliver drugs to brain tumours Dr Briony Gliddon	University of South Australia	\$0.06		
Brain organoids for rapid and personalised pre-clinical test of treatments for GBM Dr Guillermo Gomez	University of South Australia	\$0.06		
Developing a comprehensive glioblastoma brain tumour database Dr Melinda Tea	University of South Australia	\$0.03		
Developing preclinical models medulloblastoma targeting 14-3-3 Dr Melinda Tea	University of South Australia	\$0.05		
Chemotherapy effects on cognitive function in child cancer survivors Dr Alexandra Whittaker	University of Adelaide	\$0.03		
Investigating the role of 14-3-3 in medulloblastoma Dr Quenten Schwarz	University of South Australia	\$0.02		
Discovering targets for immunotherapy of aggressive childhood cancers Dr Lisa Ebert	University of South Australia	\$0.03		
Development of genetically engineered adoptive cell therapies to treat diffuse midline glioma in children Dr Tessa Gargett	University of South Australia	\$0.05		
Targeting endoplasmic reticulum-specific autophagy to treat glioblastoma Dr Nirmal Robinson	University of South Australia	\$0.03		
Developing clinically relevant models of recurrent glioblastoma Dr Mel Tea	University of South Australia	\$0.03		

Genetically engineered invariant NKT cells for dual targeting of DIPG Ms Kristyna Sedivakova	University of Adelaide	\$0.05	
Pioneering unique models of all glioblastoma subtypes to improve brain cancer treatment Dr Brett Stringer	Flinders University	\$0.04	
Predicting chemotherapeutic neurotoxicity with electrophysiological and morphological assays of human brain tissue in vitro A/Prof Cedric Bardy	Flinders University	\$0.04	
Inhibiting ER-stress induced CD47 to treat glioblastoma Dr Nirmal Robinson	University of South Australia	\$0.04	
Harnessing S1P receptor 1 to enhance CAR-T cell immunotherapy for glioblastoma Dr Briony Gliddon	University of South Australia	\$0.04	
A novel technique for defining brain tumours on MRI Dr Minh-Son To	University of South Australia	\$0.04	
Identifying mechanisms that guide T cells into tumours to improve CAR-T cell therapy for glioblastoma Dr Lisa Ebert	University of South Australia	\$0.04	
Use of artificial intelligence to identify glioblastoma patients that respond favourably to therapy Dr Guillermo Gomez	University of South Australia	\$0.04	
FAPi-MRI towards better target delineation of high-grade gliomas Prof Benjamin Thierry	University of South Australia	\$0.03	
Initiation of the KARPOS clinical trial to treat GBM (CAR-T cells) A/Prof Lisa Ebert	University of South Australia	\$0.05	
Evaluating CD47 regulated mechanisms to treat GBM Dr Nirmal Robinson	University of South Australia	\$0.05	
A new approach to enhance immunotherapy for GBM Dr Melinda Tea	University of South Australia	\$0.05	
Roles of sphingosine kinase 1 and 2 in GBM Dr Briony Gliddon	University of South Australia	\$0.05	
Limiting invasive capabilities of GBM cells Dr Sunita Ramesh	Flinders University	\$0.03	

Membrane-cholesterol depleting agents o and anti-glioma cytolytic activity of GD2- specific CAR-T cells Dr Michael Brown	University of South Australia	\$0.04	1	
EVOS M5000 microscopic imaging system Prof Stuart Pitson	University of South Australia	\$0.02	2	
Tissue dissociator and stereotactic alignment and injection system Prof Stuart Pitson	University of South Australia	\$0.0	5	
GelCount equipment Dr Melinda Tea	University of South Australia	\$0.0	5	
NRF Brain Tumour Research Chair Glioblastoma Prof Stuart Pitson	University of South Australia	\$1.00	)	
Chris Adams Scholarship - Brain Tumour Research	University of South Australia	\$0.12	2	
NRF Brain Tumour Chair Prof Stuart Pitson Scholarships	University of South Australia	\$0.03	3	
CAR-T Cell Clinical Trial Developing new immune-based therapies for brain cancer. Assoc Prof Lisa Ebert	Royal Adelaide Hospital	\$0.10	)	
Precision medical approaches for the treatment of gliomas with cannabinoids. Assoc Prof Simon Conn	Flinders University	\$0.10	)	
Developing Advanced Pre-Clinical Models of Paediatric Brain Cancers. Prof Stuart Pitson	University of South Australia and SA Pathology	\$0.10	)	
VETSCAN HM5 Haematology Analyser Dr Briony Gliddon	University of South Australia and SA Pathology	\$0.02	L	
South Australian Paediatric Brain Cancer Biobank A Prof Jordan Hansford	SAHMRI	\$0.10	)	
Establishment database management system for the South Australian Tumour Bank Dr Rebecca Ormsby	Flinders University	\$0.1	L	
Robert Connor Dawes Foundation		•		
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) <sup>1</sup>	Monash University	\$1.25	\$1.25	\$1.25

New South Wales Government				
Multiple clinical trials	Multiple sites	\$0.51	\$9.50	\$7.50
Research equipment: multiple grants	Multiple sites	\$0.24		
Research infrastructure: ACRF child cancer liquid biopsy program	Children's Cancer Institute	\$0.08		
Translational program grant: transforming protein quantitation technology to improve cancer diagnosis and treatment decisions	University of Sydney	\$0.18		
Cancer proteogenomics collaboration	Children's Medical Research Institute	\$1.02		
Zero Childhood Cancer	n/a	\$1.00		
Translational Cancer Research Centre: Centre for Oncology Education and Research Translation	University of New South Wales	\$0.46		
Translational Cancer Research Centre: Sydney Vital	University of Sydney	\$0.23		
Translational Cancer Research Centre: KIDS Cancer Alliance	University of New South Wales	\$0.23		
Early career fellowship: eradication of neuroblastoma by targeting a novel long non- protein-coding RNA	University of New South Wales	\$0.34		
Career development fellowship: towards a therapy for aggressive cancers that lack a telomere maintenance mechanism	University of Sydney	\$0.06		
Career development fellowship: Investigation on MYCN-driven mitotic deregulation in neuroblastoma	University of New South Wales	\$0.34		
Career development fellowship: an anticancer chemically-modified natural compound targeting copper in neuroblastoma	University of New South Wales	\$0.09		
Early career fellowship: improving brain cancer outcomes with MRI guided adaptive radiotherapy (INTREPID)	University of New South Wales	\$0.11		
Career development fellowship: personalising cancer radiation therapy via dynamic MRI-based adaptation to changing tumour anatomy and biology	University of Sydney	\$0.23		

Translational program grant: experimental therapeutics for Myc-driven childhood cancer	University of New South Wales		\$1.18		
Translational program grant: cancer imaging and targeted radiation therapy: innovation, discovery and translation	University of Sydney		\$0.76		
Translation program grant: implementing novel therapeutic strategies for childhood brain cancer patients	University of New South Wales		\$2.44		
Victorian Government					
Centre of Research Excellence in adult brain cancer	ONJ Research Institute		\$2.00	\$24.00	\$2.00
Centre of Research Excellence in adult brain cancer	ONJ Research Institute		\$2.00		
The Brain Cancer Centre	WEHI		\$16.00		
Gamma Knife	Peter MacCallum Cancer Centre		\$4.00		
Total		\$70.16	\$65.82	\$135.98	\$156.66

<sup>1</sup> MRFF initiative co-funded with Financial Markets Foundation for Children, the Robert Connor Dawes Foundation and Carrie's Beanies 4 Brain Cancer

<sup>2</sup> MRFF initiative co-funded with Carrie's Beanies 4 Brain Cancer

<sup>3</sup> MRFF initiative co-funded with Carrie's Beanies 4 Brain Cancer

<sup>4</sup> MRFF initiative co-funded with Carrie's Beanies 4 Brain Cancer and the Mark Hughes Foundation

<sup>5</sup> Total includes \$20m allocated to the MRFF 2024 Paediatric Brain Cancer Research grant opportunity that opened on 5 February 2024. Successful projects under this opportunity are not yet awarded.

<sup>6</sup> Cure Brain Cancer Foundation commitment to projects are not included.

<sup>7</sup> This figure represents the total the Funder has allocated to the Mission (to 2027), some of which is not yet committed to specific projects.